Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported after the close of the market on Monday that its first quarter revenues saw a 62 percent bump year over year in spite of a slowdown in product sales.

For the three months ended March 31, the firm reported $1.4 million in total revenues, compared to $865,232 in the year-ago period. While service revenues grew to $830,025 in Q1 2017 from $265,042 in Q1 2016, product revenues slid to $541,144 from $600,190.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.